Precision Medicine Diagnostics Solutions Market is expected to reach USD 122.6 billion by 2031

Precision Medicine Diagnostics Solutions Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the precision medicine diagnostics solutions market will expand from USD 65.2 billion in 2026 to USD 122.6 billion in 2031 at a CAGR of 13.5% during the forecast period.

Precision medicine diagnostics, as defined by the U.S. Food and Drug Administration (FDA), utilise genomic, environmental, and lifestyle information to create personalised disease detection and therapy options. Government-sponsored research supports the use of next-generation sequencing (NGS) as a primary technology since it allows for fast discovery of genetic changes that will guide diagnosis and therapy choice. Public programs like the Personalised Environment and Genes Study are using genomic sequencing in tandem with environmental exposure data to improve early detection of disease and predict risk factors for diseases. Thus, precision diagnostics offer a foundation for modern health systems, especially for oncology, rare diseases, and chronic disease management.

Request a free sample copy or view the report summary: Precision Medicine Diagnostics Solutions Market Report

Precision Medicine Diagnostics Solutions Market Report Highlights

• National clinical trial frameworks now rely on centralised genomic testing networks to assign therapies based on molecular profiles, improving precision oncology outcomes.

• State-backed precision medicine programs have scaled population-level genomic datasets, with over 220,000 participants contributing to diagnostic research and validation.

• Regulatory bodies are advancing flexible frameworks for next-generation sequencing diagnostics to ensure accuracy, standardisation, and clinical reliability in large-scale genomic testing.

• Government-led studies integrating genomics with environmental data are improving early disease detection models for conditions such as cardiovascular and metabolic disorders.

Precision Medicine Diagnostics Solutions Market Growth Drivers and Restraints

Growth Drivers:

• Expansion of biomarker-based diagnostics in clinical decision-making: Evidence from the government indicates that biomarker testing is currently a standard part of care, particularly in the field of oncology. According to the National Cancer Institute, biomarker tests are used to identify genes, proteins, and other molecular alterations that indicate which therapies will be most beneficial for individual patients, including targeted and immunotherapies. Additionally, these tests are used to identify patients who may be eligible for clinical trials (i.e., genomically driven “basket trials”) to improve the efficiency of treatments and trials. Moreover, there is a regulatory framework (the co-development of companion diagnostics with their corresponding drug) that ensures precision in selecting patients for these therapies. This means that today’s diagnostics provide essential access to therapies and improved outcomes as essential “gatekeepers” to therapy.

• Rapid adoption of next-generation sequencing and pharmacogenomics: Various US government agencies have identified next-generation sequencing (NGS) technologies as a foundational technology in developing precision or genome-based diagnostics. According to the US Food and Drug Administration (FDA), NGS can conduct large-scale studies of the genome and determine if a variant has the potential to cause disease, allowing clinicians to accurately diagnose and develop a treatment plan for patients. Pharmacogenomic and pharmacokinetic data, included in drug labelling, provide information to determine which patients respond to a drug, what the optimal dose should be, and how to minimise side effects from that drug. More recently, the FDA has issued further guidance (2026) relating to NGS in developing gene therapies, with recommendations for developing standardised approaches to ensure the safety and accuracy of data. Collectively, these advancements will lead to faster, more accurate, and personalised clinical decisions through integrating genome-based diagnostics into clinical decision-making for oncological and orphan diseases and chronic illnesses.

Restraints:

• Limited availability of clinically validated companion diagnostics delays accurate patient identification, restricting timely access to targeted therapies despite regulatory advancements.

Precision Medicine Diagnostics Solutions Market Key Development

• Product Launch: Roche received CE mark approval (April 2026) for its Elecsys Neurofilament Light Chain (NfL) blood test, enabling detection of neuroinflammation in multiple sclerosis and supporting earlier, biomarker-driven clinical decisions.

• Collaboration: Roche, in collaboration with KlinRisk, launched an AI-based kidney risk stratification algorithm panel (October 2025), integrating machine learning into clinical diagnostics to improve early detection and disease progression monitoring.

• Collaboration: Roche launched a large-scale AI infrastructure in partnership with NVIDIA (March 2026) to accelerate diagnostics and therapeutics development, enabling advanced data analysis and faster innovation in precision medicine solutions.

• Product launch: In October 2025, Illumina, Inc. officially launched its 5-Base solution, a novel sequencing platform that enables simultaneous detection of both genomic variants and DNA methylation from a single sample workflow. The solution uses proprietary 5-base chemistry and enhanced DRAGEN analysis to deliver high-resolution insights into both the methylome and genome, streamlining epigenetic and genetic analysis for research and clinical applications. This development improves efficiency and reduces costs for epigenetic diagnostics, particularly in oncology and rare disease biomarker discovery, and positions dual-omic testing as a scalable solution for clinical laboratories.

Precision Medicine Diagnostics Solutions Market Segmentation

Knowledge Sourcing Intelligence has segmented the Precision Medicine Diagnostics Solutions Market based on product type, technology, application, and region:

Precision Medicine Diagnostics Solutions Market, By Product Type

• Instruments

• Reagents & Kits

• Software & Services

Precision Medicine Diagnostics Solutions Market By Technology

• Polymerase Chain Reaction (PCR)

• Next-Generation Sequencing (NGS)

• Microarray

• Mass Spectrometry

• Immunoassays

Precision Medicine Diagnostics Solutions Market, By Application

• Oncology

• Neurological Disorders

• Rare Genetic Disorders

• Infectious Diseases

Precision Medicine Diagnostics Solutions Market, By Geography

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

• South America

  • Brazil

  • Argentina

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

Precision Medicine Diagnostics Solutions Market Key Players

• Roche Diagnostics

• Thermo Fisher Scientific

• Illumina

• Agilent Technologies

• QIAGEN

• Bio-Rad Laboratories

• PerkinElmer

• Diagenode

• Active Motif

• Abcam